These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

442 related articles for article (PubMed ID: 26514825)

  • 1. Characterization and Functional Analysis of scFv-based Chimeric Antigen Receptors to Redirect T Cells to IL13Rα2-positive Glioma.
    Krenciute G; Krebs S; Torres D; Wu MF; Liu H; Dotti G; Li XN; Lesniak MS; Balyasnikova IV; Gottschalk S
    Mol Ther; 2016 Feb; 24(2):354-363. PubMed ID: 26514825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. T cells redirected to interleukin-13Rα2 with interleukin-13 mutein--chimeric antigen receptors have anti-glioma activity but also recognize interleukin-13Rα1.
    Krebs S; Chow KK; Yi Z; Rodriguez-Cruz T; Hegde M; Gerken C; Ahmed N; Gottschalk S
    Cytotherapy; 2014 Aug; 16(8):1121-31. PubMed ID: 24841514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transgenic Expression of IL15 Improves Antiglioma Activity of IL13Rα2-CAR T Cells but Results in Antigen Loss Variants.
    Krenciute G; Prinzing BL; Yi Z; Wu MF; Liu H; Dotti G; Balyasnikova IV; Gottschalk S
    Cancer Immunol Res; 2017 Jul; 5(7):571-581. PubMed ID: 28550091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adoptive Transfer of IL13Rα2-Specific Chimeric Antigen Receptor T Cells Creates a Pro-inflammatory Environment in Glioblastoma.
    Pituch KC; Miska J; Krenciute G; Panek WK; Li G; Rodriguez-Cruz T; Wu M; Han Y; Lesniak MS; Gottschalk S; Balyasnikova IV
    Mol Ther; 2018 Apr; 26(4):986-995. PubMed ID: 29503195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chimeric Antigen Receptor T Cells With Modified Interleukin-13 Preferentially Recognize IL13Rα2 and Suppress Malignant Glioma: A Preclinical Study.
    Kim K; Gwak HS; Han N; Hong EK; Choi BK; Lee S; Choi S; Park JH; Seok JH; Jeon Y; Cho H; Lee SJ; Lee Y; Nam KT; Song SW
    Front Immunol; 2021; 12():715000. PubMed ID: 34819930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IL13Rα2-targeted third-generation CAR-T cells with CD28 transmembrane domain mediate the best anti-glioblastoma efficacy.
    Gu A; Bai Y; Zhang C; Xu C; An Z; Zhang Y; Zhong SH; Hu Y; Zhong X
    Cancer Immunol Immunother; 2023 Jul; 72(7):2393-2403. PubMed ID: 36991262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inclusion of 4-1BB Costimulation Enhances Selectivity and Functionality of IL13Rα2-Targeted Chimeric Antigen Receptor T Cells.
    Starr R; Aguilar B; Gumber D; Maker M; Huard S; Wang D; Chang WC; Brito A; Chiu V; Ostberg JR; Badie B; Forman SJ; Alizadeh D; Wang LD; Brown CE
    Cancer Res Commun; 2023 Jan; 3(1):66-79. PubMed ID: 36968221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suppression of human glioma xenografts with second-generation IL13R-specific chimeric antigen receptor-modified T cells.
    Kong S; Sengupta S; Tyler B; Bais AJ; Ma Q; Doucette S; Zhou J; Sahin A; Carter BS; Brem H; Junghans RP; Sampath P
    Clin Cancer Res; 2012 Nov; 18(21):5949-60. PubMed ID: 22966020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimization of IL13Rα2-Targeted Chimeric Antigen Receptor T Cells for Improved Anti-tumor Efficacy against Glioblastoma.
    Brown CE; Aguilar B; Starr R; Yang X; Chang WC; Weng L; Chang B; Sarkissian A; Brito A; Sanchez JF; Ostberg JR; D'Apuzzo M; Badie B; Barish ME; Forman SJ
    Mol Ther; 2018 Jan; 26(1):31-44. PubMed ID: 29103912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Engineered IL13 variants direct specificity of IL13Rα2-targeted CAR T cell therapy.
    Stern LA; Gholamin S; Moraga I; Yang X; Saravanakumar S; Cohen JR; Starr R; Aguilar B; Salvary V; Hibbard JC; Kalbasi A; Shepphird JK; O'Hearn J; Garcia KC; Brown CE
    Proc Natl Acad Sci U S A; 2022 Aug; 119(33):e2112006119. PubMed ID: 35939683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma.
    Brown CE; Badie B; Barish ME; Weng L; Ostberg JR; Chang WC; Naranjo A; Starr R; Wagner J; Wright C; Zhai Y; Bading JR; Ressler JA; Portnow J; D'Apuzzo M; Forman SJ; Jensen MC
    Clin Cancer Res; 2015 Sep; 21(18):4062-72. PubMed ID: 26059190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells.
    Kahlon KS; Brown C; Cooper LJ; Raubitschek A; Forman SJ; Jensen MC
    Cancer Res; 2004 Dec; 64(24):9160-6. PubMed ID: 15604287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel single-chain antibody redirects adenovirus to IL13Rα2-expressing brain tumors.
    Kim JW; Young JS; Solomaha E; Kanojia D; Lesniak MS; Balyasnikova IV
    Sci Rep; 2015 Dec; 5():18133. PubMed ID: 26656559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape.
    Hegde M; Mukherjee M; Grada Z; Pignata A; Landi D; Navai SA; Wakefield A; Fousek K; Bielamowicz K; Chow KK; Brawley VS; Byrd TT; Krebs S; Gottschalk S; Wels WS; Baker ML; Dotti G; Mamonkin M; Brenner MK; Orange JS; Ahmed N
    J Clin Invest; 2016 Aug; 126(8):3036-52. PubMed ID: 27427982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stem-like tumor-initiating cells isolated from IL13Rα2 expressing gliomas are targeted and killed by IL13-zetakine-redirected T Cells.
    Brown CE; Starr R; Aguilar B; Shami AF; Martinez C; D'Apuzzo M; Barish ME; Forman SJ; Jensen MC
    Clin Cancer Res; 2012 Apr; 18(8):2199-209. PubMed ID: 22407828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane Domains.
    Alabanza L; Pegues M; Geldres C; Shi V; Wiltzius JJW; Sievers SA; Yang S; Kochenderfer JN
    Mol Ther; 2017 Nov; 25(11):2452-2465. PubMed ID: 28807568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma.
    Bielamowicz K; Fousek K; Byrd TT; Samaha H; Mukherjee M; Aware N; Wu MF; Orange JS; Sumazin P; Man TK; Joseph SK; Hegde M; Ahmed N
    Neuro Oncol; 2018 Mar; 20(4):506-518. PubMed ID: 29016929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel ligand delivery system to non-invasively visualize and therapeutically exploit the IL13Rα2 tumor-restricted biomarker.
    Nguyen V; Conyers JM; Zhu D; Gibo DM; Hantgan RR; Larson SM; Debinski W; Mintz A
    Neuro Oncol; 2012 Oct; 14(10):1239-53. PubMed ID: 22952195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel anti-GD2/4-1BB chimeric antigen receptor triggers neuroblastoma cell killing.
    Prapa M; Caldrer S; Spano C; Bestagno M; Golinelli G; Grisendi G; Petrachi T; Conte P; Horwitz EM; Campana D; Paolucci P; Dominici M
    Oncotarget; 2015 Sep; 6(28):24884-94. PubMed ID: 26298772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin-13 receptor alpha 2-targeted glioblastoma immunotherapy.
    Sengupta S; Thaci B; Crawford AC; Sampath P
    Biomed Res Int; 2014; 2014():952128. PubMed ID: 25247196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.